AstraZeneca to cut some direct-to-patient US drug prices after Trump demand
PositiveFinancial Markets

AstraZeneca has announced plans to reduce certain direct-to-patient drug prices in the U.S. following a demand from former President Trump. This move is significant as it reflects a growing trend among pharmaceutical companies to address drug affordability, which has been a major concern for many Americans. By lowering prices, AstraZeneca aims to improve access to essential medications, potentially benefiting countless patients who struggle with high healthcare costs.
— Curated by the World Pulse Now AI Editorial System